Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00

Denali Therapeutics (NASDAQ:DNLI) had its price objective boosted by Morgan Stanley from $40.00 to $42.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts have also issued reports on DNLI. Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a research report on Friday, August 7th. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Denali Therapeutics in a research report on Wednesday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Thursday, October 15th. Finally, UBS Group lifted their price objective on Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.15.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI traded up $0.35 during midday trading on Wednesday, reaching $20.07. 1,586,647 shares of the company’s stock traded hands, compared to its average volume of 1,699,561. The company has a fifty day simple moving average of $20.16 and a two-hundred day simple moving average of $21.27. Denali Therapeutics has a 1 year low of $13.75 and a 1 year high of $27.30. The company has a market cap of $3.21 billion, a P/E ratio of -11.60 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.64. The company had revenue of $17.78 million during the quarter, compared to analysts’ expectations of $12.67 million. During the same period in the previous year, the firm posted ($0.74) EPS. Equities analysts predict that Denali Therapeutics will post -2.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the transaction, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in shares of Denali Therapeutics by 21.7% during the 1st quarter. Bank of America Corp DE now owns 1,134,183 shares of the company’s stock worth $21,776,000 after acquiring an additional 202,039 shares during the period. Legal & General Group Plc acquired a new position in shares of Denali Therapeutics during the 2nd quarter valued at about $2,879,000. Great Lakes Advisors LLC acquired a new position in shares of Denali Therapeutics during the 2nd quarter valued at about $3,731,000. Engineers Gate Manager LP grew its holdings in shares of Denali Therapeutics by 256.5% in the second quarter. Engineers Gate Manager LP now owns 57,430 shares of the company’s stock valued at $1,477,000 after purchasing an additional 41,320 shares during the period. Finally, E. Ohman J or Asset Management AB purchased a new stake in shares of Denali Therapeutics in the second quarter valued at about $4,115,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s third-quarter results beat expectations: EPS was $0.37 versus the consensus estimate of a $0.27 loss, and revenue was $17.78 million versus a $12.67 million estimate. Denali Therapeutics earnings beat and valuation article
• Positive Sentiment: Commercial momentum and potential catalysts may be lifting sentiment: a report cited nearly fivefold growth in Avlayah sales, broader reimbursement coverage, and multiple upcoming pipeline catalysts. Shares were reported up 7.8% after the earnings release. Zacks report on Denali post-earnings performance
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong Buy” rating, providing a new bullish analyst view. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s forecasts show losses continuing in coming years, though its estimates narrow to a $0.14-per-share loss by 2030. The longer-term outlook is therefore still dependent on commercial growth and pipeline progress.
• Neutral Sentiment: A separate report put Denali’s valuation back in focus after the earnings-driven move, suggesting investors may weigh the improved results against the stock’s valuation. Denali earnings and valuation article

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.